Hepatitis B Topics HBV Treatment
EASL: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- Details
- Category: HBV Treatment
- Published on Tuesday, 24 April 2012 00:00
- Written by Liz Highleyman
No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.
Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 27 December 2011 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for the nucleoside analog telbivudine (Tyzeka), indicating that it should not be used with pegyalted interferon alfa-2a (brand name Pegasys) for the treatment of hepatitis B because the combination can cause peripheral neuropathy, or nerve damage.
EASL International Liver Congress Starts This Week in Barcelona
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) takes place this week, April 18-22, in Barcelona. HIVandHepatitis.com will be on site to provide breaking news and analysis.
Top 10 HIV and Hepatitis Stories of 2011
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
In our last issue for 2011, HIVandHepatitis.com reviews some the year's major news highlights. HIV prevention garnered the most headlines, with studies showing that antiretroviral therapy (ART) prevents transmission and pre-exposure prophylaxis (PrEP) works -- at least for some people some of the time. On the hepatitis C front, the first new direct-acting antiviral drugs were approved, ushering in a new era of more effective treatment.
More Articles...
- AASLD: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
- AASLD: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression
- AASLD: Long-term Tenofovir for HIV/HBV Coinfection
- AASLD: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis
Web Design and Development by